Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from EQS Group

07:53 EST 13th December 2018 | BioPortfolio

Here are the most relevant search results for "EQS Group" found in our extensive news archives from over 250 global news sources.

More Information about EQS Group on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about EQS Group for you to read. Along with our medical data and news we also list EQS Group Clinical Trials, which are updated daily. BioPortfolio also has a large database of EQS Group Companies for you to search.

Showing News Articles 1–25 of 1,000+ from EQS Group

Thursday 13th December 2018

Vicore Pharma Holding AB (VICO-SE): Funded through 2021E beyond key inflection points

goetzpartners securities Limited 13-Dec-2018 / 10:38 GMT/BST Free to access research and investor meetings in a post-MiFID2 world. This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clien...

Medios AG expands its Management Board

DGAP-News: Medios AG / Key word(s): Miscellaneous 13.12.2018 / 09:34 The issuer is solely responsible for the content of this announcement. Corporate News Medios AG expands its Management Board As new member of the Management Board and Chief Innovation Officer (CIO) from 1 January 2019, Christoph Prußeit will - among others - assume responsibility for the Manufacturing division. ...

Biofrontera AG: Voluntary review of the February 2018 share issuance dismisses allegations

DGAP-News: Biofrontera AG / Key word(s): Statement 13.12.2018 / 09:30 The issuer is solely responsible for the content of this announcement. Voluntary review of the February 2018 share issuance dismisses allegations Independent review concludes that allegations of illegitimacy regarding Biofrontera's February 2018 capital increase are unfounded. Biofrontera AG had announced in July ...

Wednesday 12th December 2018

Edison Investment Research Limited: Edison issues outlook on e-Therapeutics (ETX)

Edison Investment Research Limited 12-Dec-2018 / 13:01 GMT/BST London, UK, 12 December 2018 Edison issues outlook on e-Therapeutics (ETX) e-Therapeutics (ETX) has announced a long-awaited research collaboration with Novo Nordisk (Novo) on early target discovery in diabetes. This is the first commercial collaboration in ETX's history and will last for at least a year. The financial terms...

Vita 34 records increasing number of uses of umbilical cord blood

DGAP-News: Vita 34 AG / Key word(s): Miscellaneous 12.12.2018 / 13:56 The issuer is solely responsible for the content of this announcement. Vita 34 records increasing number of uses of umbilical cord blood - Already 5th application from stock in the current year - Noticeably increasing number of use cases - Highest number of applications within one year Leipzig, 12 December 2018 - ...

MorphoSys's Licensee Janssen Announces Data from the Phase 3 Head-to-Head Study ECLIPSE Demonstrating Superiority of Tremfya(R) vs. Cosentyx(R) as Measured by PASI 90 at Week 48 in the Treatment of Plaque Psoriasis (news with additional features)

DGAP-News: MorphoSys AG / Key word(s): Study results 12.12.2018 / 13:36 The issuer is solely responsible for the content of this announcement. Planegg/Munich, Germany, December 12, 2018   MorphoSys's Licensee Janssen Announces Data from the Phase 3 Head-to-Head Study ECLIPSE Demonstrating Superiority of Tremfya(R) vs. Cosentyx(R) as Measured by PASI 90 at Week 48 in the Treatment ...

Biotest AG: Correction of a release from 11/12/2018 according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Biotest AG 12.12.2018 / 13:24 Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Notification of Major Holdings 1. Details of issuer Name: Biotest AG Street: Landsteinerstraße 5 Postal code: 63303 City: DreieichGermany Legal Entity Identifier (LEI): ...

CO.DON AG: Delivery of machinery to Leipzig site complete

DGAP-News: CO.DON AG / Key word(s): Expansion 12.12.2018 / 11:00 The issuer is solely responsible for the content of this announcement. CO.DON AG - Delivery of machinery to Leipzig site complete Berlin / Teltow, 12.12.2018 - Only 11 months after the contract was signed, the clean room technology for the new production site has all been delivered. The components were transported from B...

Tuesday 11th December 2018

MetrioPharm AG: MetrioPharm AG Closes Financing Round of CHF 20 Million

EQS Group-News: MetrioPharm AG / Key word(s): Financing/Capital Increase 11.12.2018 / 16:46 Zurich, December 11, 2018. MetrioPharm AG, a clinical stage pharmaceutical development company, announces that it has successfully completed the current financing round D. MetrioPharm CEO Dr. Wolfgang Brysch: "We are pleased to have completed the current financing round as planned in 2018. Altoget...

Siemens Healthineers AG: Announcement of the Convening of the General Meeting in München on 05.02.2019 according to article 121 AktG (German Stock Companies Act) with the objective of Europe-wide distribution

DGAP-News: Siemens Healthineers AG / Announcement of the Convening of the General Meeting 11.12.2018 / 15:02 Announcement according to article 121 AktG (German Stock Companies Act), transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Siemens Healthineers AG announces the convening of the General Meeting.Please find the ...

Edison initiates coverage of ADL Bionatur Solutions forecasting an equity valuation of EUR 2.37 per share with an upside potential of 42%

DGAP-News: ADL Bionatur Solutions / Key word(s): Research Update 11.12.2018 / 10:40 The issuer is solely responsible for the content of this announcement. Edison initiates coverage of ADL Bionatur Solutions forecasting an equity valuation of EUR 2.37 per share with an upside potential of 42% - Potential upside of more than 42% compared to MAB closing price of EUR 1.66 on 10 December 20...

B.R.A.I.N. Biotechnology Research And Information Network AG: Nature-based freshness and product stability - Global beverage company joins BRAIN's newly established FRESCO program for nature-based preservation ingredients

DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG / Key word(s): Alliance 11.12.2018 / 08:50 The issuer is solely responsible for the content of this announcement. Nature-based freshness and product stability Global beverage company joins BRAIN's newly established FRESCO program for nature-based preservation ingredients Joint efforts to address growing demand fo...

Hardman & Co Research: genedrive plc (GDR): Accelerating into fiscal 2019 with first sales

Hardman & Co Research 11-Dec-2018 / 07:15 GMT/BST Hardman & Co: Accelerating into fiscal 2019 with first sales genedrive plc (GDR) is a commercial-stage company focused on point-of-care molecular diagnostics. Its Genedrive(R) molecular diagnostic testing platform is at the forefront of this technology, offering a rapid, low-cost, simple-to-use device with high sensitivity and specifi...

Douglas announces FY2017/18 results

Douglas shifts to growth mode Sales increase by 17 percent to 3.3 billion euros in fiscal year 2017/18  Double-digit growth in e-commerce  Reorganization delivers initial promising results  German business returns to growth in final quarter  CEO Tina Müller: “We  have created  the  foundations  for  sustainable,  profitable growth.” Düsseldorf,  11 December  2018. Douglas, Euro...

Monday 10th December 2018

Amyris and ADL Bionatur Solutions Expand Production Agreement to Meet Growing Demand

DGAP-News: ADL Bionatur Solutions / Key word(s): Contract 10.12.2018 / 10:45 The issuer is solely responsible for the content of this announcement. Amyris and ADL Bionatur Solutions Expand Production Agreement to Meet Growing Demand EMERYVILLE, California, USA and León, Spain - December 10, 2018.- Amyris, Inc. (Nasdaq:AMRS), a leader in the development and production of pure, sustaina...

DGAP-DD: curasan AG english

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 10.12.2018 / 10:31 The issuer is solely responsible for the content of this announcement. 1. Details of the person discharging managerial responsibilities / person closely associated a) Name Title: First name: Mi...

Hardman & Co Research: Avacta (AVCT): Wake-up call for the market

Hardman & Co Research 10-Dec-2018 / 07:30 GMT/BST Hardman & Co: Wake-up call for the market Avacta (AVCT) is a pre-clinical stage biotechnology company and the proprietary owner of Affimer technology. Affimers represent a radical alternative to the established antibody technology. The significant technical and commercial benefits of Affimers are being recognised increasingly through ...

Friday 7th December 2018

Resaphene Suisse AG: European Patent Office announces patent for tinnitus therapy (news with additional features)

Resaphene Suisse AG / Key word(s): Patent Resaphene Suisse AG: European Patent Office announces patent for tinnitus therapy 07-Dec-2018 / 21:54 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Roggwil, December 7...

Fresenius SE & Co. KGaA: Delaware Supreme Court upholds Fresenius' termination of merger agreement with Akorn

Fresenius SE & Co. KGaA / Key word(s): Legal Matter Fresenius SE & Co. KGaA: Delaware Supreme Court upholds Fresenius' termination of merger agreement with Akorn 07-Dec-2018 / 18:52 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this...

Hardman & Co Research: Gateley (Holdings) Plc (GTLY): Strong trading and industry opportunity

Hardman & Co Research 07-Dec-2018 / 16:40 GMT/BST Hardman & Co: Strong trading and industry opportunity Gateley's trading statement in respect of 1H 2019 was sparkling, with 20% revenue growth in 1H and a highly confident outlook for 2H. We expect to revise our forecasts up by £2m at the revenue line and by more than £0.5m in EBITDA with the interims, a highly positive picture 7 mo...

Ad hoc: MorphoSys Announces that According to a Presentation Title at an Upcoming Conference, Guselkumab Demonstrates Superior Long-Term Responses to Secukinumab at Week 48 in the Treatment of Moderate to Severe Psoriasis

MorphoSys AG / Key word(s): Miscellaneous Ad hoc: MorphoSys Announces that According to a Presentation Title at an Upcoming Conference, Guselkumab Demonstrates Superior Long-Term Responses to Secukinumab at Week 48 in the Treatment of Moderate to Severe Psoriasis 07-Dec-2018 / 13:21 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, tran...

Thursday 6th December 2018

Fresenius Medical Care gives early preliminary indicative guidance for 2019

DGAP-News: Fresenius Medical Care AG & Co. KGaA / Key word(s): Forecast 06.12.2018 / 23:16 The issuer is solely responsible for the content of this announcement. December 6, 2018 Fresenius Medical Care gives early preliminary indicative guidance for 2019 - For 2019, an indicative and preliminary assumption of solid revenue growth on a comparable basis[1] net income[2] at around th...

Fresenius Medical Care AG & Co. KGaA gives early preliminary indicative guidance for 2019

Fresenius Medical Care AG & Co. KGaA / Key word(s): Forecast Fresenius Medical Care AG & Co. KGaA gives early preliminary indicative guidance for 2019 06-Dec-2018 / 22:35 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announceme...

Fresenius SE & Co. KGaA: Fresenius expects mid-single digit organic growth in the medium-term, after strong investment year 2019

Fresenius SE & Co. KGaA / Key word(s): Forecast Fresenius SE & Co. KGaA: Fresenius expects mid-single digit organic growth in the medium-term, after strong investment year 2019 06-Dec-2018 / 22:30 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the ...

Edison initiates coverage on OSE Immunotherapeutics (OSE)

Edison Investment Research Limited 06-Dec-2018 / 15:06 GMT/BST London, UK, 6 December 2018 Edison initiates coverage on OSE Immunotherapeutics (OSE) OSE Immunotherapeutics (OSE) is a drug developer that focuses on both oncology and immune disorders, with an R&D pipeline diversified across different indications and mechanisms of action. Long-term collaborations with top research inst...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks